Dermatologic manifestations of COVID-19: a comprehensive systematic review - PubMed (original) (raw)

. 2021 Apr;60(4):418-450.

doi: 10.1111/ijd.15168. Epub 2020 Nov 3.

Affiliations

• PMID: 33141443
• DOI: 10.1111/ijd.15168

Dermatologic manifestations of COVID-19: a comprehensive systematic review

Fatima N Mirza et al. Int J Dermatol. 2021 Apr.

Abstract

Recent reports have suggested that there may be dermatologic manifestations of COVID-19. We searched 12 databases for peer-reviewed or pre-print published studies until July 15, 2020, for this PRISMA-compliant review (CRD42020182050). We used the Oxford Center for Evidence-Based Medicine Levels of Evidence to facilitate data synthesis. From 86 retrieved studies, we collated data on 2,560 patients with dermatologic manifestations of COVID-19. The most common findings were chilblains/pernio-like lesion (51.5%), erythematous maculopapular rashes (13.3%), and viral exanthem (7.7%). Average pediatric age was 12.9 years (SD 3.6) and adult was 34.2 years (SD 21.8). Average latency from time of upper respiratory illness symptoms to cutaneous findings was 1.5 days (SD 2.9) in children and 7.9 days (SD 10.7) in adults, ranging from -3 to 38 days. Roughly one-tenth in both populations were otherwise asymptomatic or presented with only skin findings for the entirety of the disease course; 13.3% (pediatrics) and 5.3% (adults) presented with skin issues first. Dermatologic findings may play an important role in identifying cases early and serve as an important proxy to manage spread. Further prospective data collection with international prospective registries is needed.

© 2020 The International Society of Dermatology.

PubMed Disclaimer

Similar articles

• Cutaneous Manifestations of COVID-19: An Evidence-Based Review.
  Daneshgaran G, Dubin DP, Gould DJ. Daneshgaran G, et al. Am J Clin Dermatol. 2020 Oct;21(5):627-639. doi: 10.1007/s40257-020-00558-4. Am J Clin Dermatol. 2020. PMID: 32865778 Free PMC article. Review.
• Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries.
  Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Takeshita J, French LE, Thiers BH, Hruza GJ, Fox LP; American Academy of Dermatology Ad Hoc Task Force on COVID-19. Freeman EE, et al. J Am Acad Dermatol. 2020 Aug;83(2):486-492. doi: 10.1016/j.jaad.2020.05.109. Epub 2020 May 30. J Am Acad Dermatol. 2020. PMID: 32479979 Free PMC article.
• Cutaneous manifestations of COVID-19 in children (and adults): A virus that does not discriminate.
  Lavery MJ, Bouvier CA, Thompson B. Lavery MJ, et al. Clin Dermatol. 2021 Mar-Apr;39(2):323-328. doi: 10.1016/j.clindermatol.2020.10.020. Epub 2020 Nov 1. Clin Dermatol. 2021. PMID: 34272030 Free PMC article. Review.
• Cutaneous Manifestations of COVID-19: A Systematic Review.
  Singh H, Kaur H, Singh K, Sen CK. Singh H, et al. Adv Wound Care (New Rochelle). 2021 Feb;10(2):51-80. doi: 10.1089/wound.2020.1309. Epub 2020 Oct 19. Adv Wound Care (New Rochelle). 2021. PMID: 33035150 Free PMC article.
• The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review.
  Rajan M B, Kumar-M P, Bhardwaj A. Rajan M B, et al. Int J Dermatol. 2020 Nov;59(11):1358-1370. doi: 10.1111/ijd.15154. Epub 2020 Sep 16. Int J Dermatol. 2020. PMID: 32936462

Cited by

• Prevalence of skin manifestations in patients with COVID-19: a systematic review and meta-analysis.
  de Aguiar BRL, Ferreira EB, De Luca Canto G, Guerra ENS, Dos Reis PED. de Aguiar BRL, et al. Front Med (Lausanne). 2024 Aug 21;11:1390775. doi: 10.3389/fmed.2024.1390775. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39234048 Free PMC article.
• Research progress of post-acute sequelae after SARS-CoV-2 infection.
  Jiao T, Huang Y, Sun H, Yang L. Jiao T, et al. Cell Death Dis. 2024 Apr 11;15(4):257. doi: 10.1038/s41419-024-06642-5. Cell Death Dis. 2024. PMID: 38605011 Free PMC article. Review.
• Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response.
  Verma A, Manojkumar A, Dhasmana A, Tripathi MK, Jaggi M, Chauhan SC, Chauhan DS, Yallapu MM. Verma A, et al. Nanotheranostics. 2024 Feb 25;8(2):247-269. doi: 10.7150/ntno.91910. eCollection 2024. Nanotheranostics. 2024. PMID: 38444741 Free PMC article. Review.
• SARS-COV-2 MRNA vaccine-associated cutaneous vasculitis.
  Erol VB, Can M. Erol VB, et al. North Clin Istanb. 2023 Nov 21;10(6):816-818. doi: 10.14744/nci.2022.22309. eCollection 2023. North Clin Istanb. 2023. PMID: 38328731 Free PMC article.
• Impacts of SARS-CoV-2 on diabetes mellitus: A pre and post pandemic evaluation.
  Nabi AHMN, Ebihara A, Shekhar HU. Nabi AHMN, et al. World J Virol. 2023 Jun 25;12(3):151-171. doi: 10.5501/wjv.v12.i3.151. World J Virol. 2023. PMID: 37396707 Free PMC article. Review.

References

1. 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20: 533-534.
2. 1. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708-1720.
3. 1. Howick J, Chalmers I, Glasziou P, et al. The 2011 Oxford CEBM levels of evidence. 2011. Available at http://www.cebm.net/index.aspx?o=5653. Accessed January 31, 2017.
4. 1. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009; 6: e1000097.
5. 1. Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol 2020; 83: 486-492.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information